Samar S Al-Harbi*, Shahira A Hassoubah and Bothaina A Alaidaroos

Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

*Corresponding Author: Samar S Al-Harbi, Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

Received: July 30, 2025; Published: August 13, 2025

Abstract

The global escalation of antimicrobial resistance (AMR) has intensified the search for new bioactive molecules, particularly from marine environments. Coral reefs are among the planet’s most biodiverse ecosystems, harboring intricate microbiomes in which coral-associated bacteria (CAB) play pivotal roles in host nutrition, immunity, and pathogen exclusion. Genera such as Bacillus, Streptomyces, Pseudoalteromonas, and Endozoicomonas synthesize a chemically diverse array of secondary metabolites, including polyketides, lipopeptides, alkaloids, and terpenes, which display broad-spectrum antibacterial, antifungal, cytotoxic, and anti-inflammatory activities.

These metabolites not only defend corals against pathogens and biofouling but also hold promise as drug leads against multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus, Escherichia coli, and Candida albicans. Investigations, particularly from the Red Sea, continue to reveal novel compounds such as aqabamycins, actinosporins, and saadamycin, underscoring the remarkable chemical richness of CAB and the Red Sea’s status as an underexplored reservoir of antimicrobial scaffolds.

This review first surveys bioactive natural products from terrestrial and marine origins to provide context for CAB-derived chemistry. It then synthesizes the latest findings on the diversity, biosynthesis, and antimicrobial modes of action of CAB metabolites, with a special focus on Red Sea isolates. By highlighting both ecological function and pharmaceutical potential, we emphasize the enormous yet largely untapped capacity of CAB to yield next-generation therapeutics and advocate for intensified bioprospecting, genome-guided discovery, and pharmacological evaluation to help curb the AMR crisis.

 Keywords: Coral Reef; Coral-Associated Bacteria (CAB); Red Sea; Antimicrobial Compounds; Antimicrobial Resistance (AMR); Marine Natural Products

References

1. Palma Esposito F., et al. “Novel insights and genomic characterization of coral-associated microorganisms from Maldives displaying antimicrobial, antioxidant, and UV-protectant activities”. Biology 14 (2025): 401.
2. Sonya Tururaja T., et al. “Antibacterial activity of the soft coral symbiont bacteria Sarcophyton sp. against Escherichia coli and Staphylococcus aureus bacteria in the waters of Lemon Island and Kaki Island, Manokwari”. BIO Web Conf 176 (2025): 02004.
3. Modolon F., et al. “Ecological and biotechnological importance of secondary metabolites produced by coral‐associated bacteria”. Journal of Applied Microbiology 129 (2020): 1441-
4. El-Gendy MMAA., et al. “Assessment of the phylogenetic analysis and antimicrobial, antiviral, and anticancer activities of marine endophytic Streptomyces species of the soft coral Sarcophyton convolutum”. International Microbiology 25 (2022): 133-152.
5. Krishnamoorthy M., et al. “Pharmacological activities of coral reef associated actinomycetes, Saccharopolyspora sp. IMA1”. Biocatalysis and Agricultural Biotechnology 28 (2020): 101748.
6. Kvennefors ECE., et al. “Regulation of bacterial communities through antimicrobial activity by the coral holobiont”. Microbe Ecology 63 (2012): 605-618.
7. Sweet MJ and Bulling MT. “On the importance of the microbiome and pathobiome in coral health and disease”. Frontiers in Marine Science 4 (2017): 9.
8. Bush K and Bradford PA. “β-Lactams and β-lactamase inhibitors: an overview”. Cold Spring Harbor Perspectives in Medicine 6 (2016): a025247.
9. Pandey N and Cascella M. “Beta-lactam antibiotics”. StatPearls (2023).
10. Singh SP., et al. “Mechanisms of action by antimicrobial agents: a review”. McGill Journal of Medicine 19 (2021): 1.
11. Al-Zereini W., et al. “Aqabamycins A-G: novel nitro maleimides from a marine Vibrio species. I. Taxonomy, fermentation, isolation and biological activities”. Journal of Antibiotics 63 (2010): 297-301.
12. Minkah C., et al. “Antimicrobial compounds from microorganisms”. Antibiotics 11 (2022): 285.
13. Walia A., et al. “Role of bioactive compounds in human health”. Acta Scientific Medical Sciences (2019).
14. Biesalski HK., et al. “Bioactive compounds: definition and assessment of activity”. Nutrition 25 (2009): 1202-1205.
15. Pascoal A., et al. “An overview of the bioactive compounds, therapeutic properties and toxic effects of apitoxin”. Food Chemistry Toxicology 134 (2019): 110864.
16. Rani A., et al. “A review on microbial products and their perspective application as antimicrobial agents”. Biomolecules 11 (2021): 1860.
17. Martín Ortega AM and Segura Campos MR. “Bioactive compounds as therapeutic alternatives”. Bioactive Compounds: Health Benefits and Potential Applications (2019): 247-264.
18. Jaka H., et al. “Antimicrobial resistance: Mechanisms of action of antimicrobial agents”.
19. Aware CB., et al. “Natural bioactive products as promising therapeutics: A review of natural product-based drug development”. South African Journal of Botany 151 (2022): 512-528.
20. Newman DJ and Cragg GM. “Plant endophytes and epiphytes: burgeoning sources of known and “unknown” cytotoxic and antibiotic agents?” Planta Medica 86 (2020): 891-905.
21. Rawlings BJ. “Type I polyketide biosynthesis in bacteria (Part B)”. Natural Product Reports 18 (2001): 231-281.
22. Radjasa OK and Sabdono A. “Screening of secondary metabolite-producing bacteria associated with corals using 16S rDNA-based approach”. Journal of Coastal Conservation 7 (2003): 1.
23. Shimamura H., et al. “Structure determination and total synthesis of bottromycin A2: a potent antibiotic against MRSA and VRE”. Angewandte Chemie International Edition 48 (2009): 914-917.
24. Ohnishi Y., et al. “Genome sequence of the streptomycin-producing microorganism Streptomyces griseus IFO 13350”. Journal of Bacteriology11 (2008): 4050-4060.
25. Siro G., et al. “Marine actinomycetes associated with stony corals: a potential hotspot for specialized metabolites”. Microorganisms 10 (2022): 1349.
26. Hoshino T. “Violacein and related tryptophan metabolites produced by Chromobacterium violaceum: biosynthetic mechanism and pathway for construction of violacein core”. Applied Microbiology and Biotechnology 91 (2011): 1463-1475.
27. López-Agudelo VA., et al. “Clavulanic acid production by Streptomyces clavuligerus: insights from systems biology, strain engineering, and downstream processing”. Antibiotics1 (2021): 84.
28. Kaspar F., et al. “Bioactive secondary metabolites from Bacillus subtilis: a comprehensive review”. Journal of Natural Products 82 (2019): 2038-2053.
29. Rodríguez-Cisneros M., et al. “Compilation of the antimicrobial compounds produced by Burkholderia sensu stricto”. Molecules 28 (2023): 1646.
30. Dreyer J., et al. “Bacteria of the genus Xenorhabdus, a novel source of bioactive compounds”. Frontiers in Microbiology 9 (2018): 3177.
31. Valença CAS., et al. “Volatile nitrogenous compounds from bacteria: source of novel bioactive compounds”. Chemistry and Biodiversity 18 (2021): e2100549.
32. Xu M., et al. “Fusarium-derived secondary metabolites with antimicrobial effects”. Molecules 28 (2023): 3424.
33. Twaij BM and Hasan MN. “Bioactive secondary metabolites from plant sources: types, synthesis, and their therapeutic uses”. International Journal of Plant Biology 13 (2022): 4-14.
34. Zhao L., et al. “Isolation and anticancer progression evaluation of the chemical constituents from Bridelia balansae Tutcher”. Molecules 28 (2023): 6165.
35. Tang TT., et al. “Identification of flavonoids from Scutellaria barbata D. Don as inhibitors of HIV-1 and cathepsin L proteases and their structure-activity relationships”. Molecules 28 (2023): 4476.
36. Lindequist U. “Marine-derived pharmaceuticals—challenges and opportunities”. Biomolecular Therapy 24 (2016): 561-571.
37. Burkholder PR and Ruetzler K. “Antimicrobial activity of some marine sponges”. Nature5197 (1979): 983-984.
38. Pérez MJ., et al. “Antimicrobial action of compounds from marine seaweed”. Marine Drugs 14 (2021): 52.
39. Sibiya A., et al. “Bioactive compounds from various types of sea urchin and their therapeutic effects - a review”. Regional Studies in Marine Science 44 (2021): 101760.
40. Karthikeyan A., et al. “Promising bioactive compounds from the marine environment and their potential effects on various diseases”. Journal of Genetic Engineering and Biotechnology 20 (2022): 1-38.
41. Santos JD., et al. “From ocean to medicine: pharmaceutical applications of metabolites from marine bacteria”. Antibiotics 9 (2020): 455.
42. Wiese J., et al. “Bacicyclin, a new antibacterial cyclic hexapeptide from Bacillus sp. strain BC028 isolated from Mytilus edulis”. Bioorganic and Medicinal Chemistry Letters 28 (2018): 558-561.
43. Stincone P and Brandelli A. “Marine bacteria as source of antimicrobial compounds”. Critical Reviews in Biotechnology 40 (2020): 306-319.
44. Caulier S., et al. “Overview of the antimicrobial compounds produced by members of the Bacillus subtilis group”. Frontiers in Microbiology 10 (2019): 302.
45. Alahmari AN., et al. “Sponges-associated marine bacteria as sources of antimicrobial compounds”. Novel Research in Microbiology Journal5 (2022).
46. Zhang D., et al. “New antibacterial bagremycins F and G from the marine-derived Streptomyces sp. ZZ745”. Marine Drugs 16 (2018): 330.
47. Wibowo D., et al. “Antimicrobial activity of fatty acid derivatives produced by Micrococcus luteus isolated from marine sediment”. Marine Biotechnology 27 (2025): 112-123.
48. Boudrahem D., et al. “Exploring marine-derived bacterial compounds targeting the μ-opioid receptor agonists through metabolic profiling to molecular modeling”. Scientific Reports 15 (2025): 17196.
49. Kim H., et al. “2-Alkyl-4-hydroxyquinolines from a marine-derived Streptomyces sp. inhibit hyphal growth induction in Candida albicans”. Marine Drugs 17 (2021): 133.
50. Hwengwere K., et al. “Psychrotrophic Antarctic marine bacteria as potential reservoirs for novel antimicrobial genes”. FEMS Microbes 6 (2025): xtaf004.
51. Nguyen VT., et al. “Exploring Pediococcus sp. M21F004 for biocontrol of bacterial and fungal phytopathogens”. Marine Drugs 22 (2024): 534.
52. Feling RH., et al. “Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinispora”. Angewandte Chemie International Edition3 (2003): 355-357.
53. Isnansetyo A and Kamei Y. “MC21-A, a bactericidal antibiotic produced by a new marine bacterium, Pseudoalteromonas phenolica sp. nov. O-BC30T, against methicillin-resistant Staphylococcus aureus”. Antimicrobial Agents and Chemotherapy2 (2003): 480-488.
54. Li Q., et al. “Peniciphenalenins A-F from the culture of a marine-associated fungus Penicillium sp. ZZ901”. Phytochemistry 152 (2018): 53-60.
55. Ramesh S and Mathivanan N. “Screening of marine actinomycetes for antimicrobial compounds”. Research Journal of Microbiology3 (2009): 155-162.
56. Li J., et al. “Discovery of albofungin as a potent antimicrobial agent against multidrug-resistant Gram-negative bacteria”. Acta Pharmaceutica Sinica B8 (2021): 2524-2533.
57. Shaala LA., et al. “Antimicrobial chlorinated 3-phenylpropanoic acid derivatives from the Red Sea marine actinomycete Streptomyces coelicolor LY001”. Marine Drugs 18 (2020): 450.
58. Maire J., et al. “Intracellular bacterial symbionts in corals: challenges and future directions”. Microorganisms 9 (2021): 2209.
59. Delgadillo-Ordoñez N., et al. “Red Sea atlas of coral-associated bacteria highlights common microbiome members and their distribution across environmental gradients—A systematic review”. Microorganisms 10 (2022): 2340.
60. Hsieh YE., et al. “Successive responses of three coral holobiont components (coral hosts, symbiotic algae, and bacteria) to daily temperature fluctuations”. Ecological Indicators 158 (2024): 111515.
61. Maire J., et al. “Tissue-associated and vertically transmitted bacterial symbiont in the coral Pocillopora acuta”. ISME Journal 18 (2024): 1-5.
62. Kanisan DP., et al. “Diversity and distribution of microbial communities associated with reef corals of the Malay Peninsula”. Microbial Ecology 85 (2023): 37-48.
63. Zhang X., et al. “Phylogenetic survey and antimicrobial activity of culturable microorganisms associated with the South China Sea black coral Antipathes dichotoma”. FEMS Microbiology Letters 336 (2012): 122-130.
64. Gao CH., et al. “Antibacterial and antilarval compounds from marine gorgonian-associated bacterium Bacillus amyloliquefaciens SCSIO 00856”. Journal of Antibiotics 63 (2010): 191-193.
65. Atencio LA., et al. “Antimicrobial-producing Pseudoalteromonas from the marine environment of Panama shows a high phylogenetic diversity and clonal structure”. Journal of Basic Microbiology9 (2018): 747-769.
66. Fu P., et al. “Antibiotic metabolites from the coral‐associated actinomycete Streptomyces sp. OUCMDZ‐1703”. Chinese Journal of Chemistry 31 (2013): 100-
67. Moree WJ., et al. “Imaging mass spectrometry of a coral microbe interaction with fungi”. Journal of Chemical Ecology 39 (2013): 1045-1054.
68. Gómez-Betancur I., et al. “Bioactive compounds isolated from marine bacterium Vibrio neocaledonicus and their enzyme inhibitory activities”. Marine Drugs 17 (2019): 401.
69. Steen AD., et al. “High proportions of bacteria and archaea across most biomes remain uncultured”. ISME Journal 13 (2019): 3126-3130.
70. Afouda P., et al. “Integrated multi-omics reveals the functional roles of uncultivated bacteria in coral health and stress responses”. Nature Microbiology 8 (2023): 451-462.

Citation

Citation: Samar S Al-Harbi., et al. “Harnessing the Antimicrobial Potential of Red Sea Coral-Associated Bacteria: Current Insights and Future Directions”.Acta Scientific Medical Sciences 9.9 (2025): 31-45.

Copyright

Copyright: © 2025 Samar S Al-Harbi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.